<span class="anchor" id="L04A"></span>L04A Immunosuppressants
<span class="anchor" id="L04AA"></span>L04AA Selective immunosuppressants
:L04AA03 Antilymphocyte immunoglobulin (horse)
:L04AA04 Antithymocyte immunoglobulin (rabbit)
:L04AA06 Mycophenolic acid
:L04AA15 Alefacept
:L04AA19 Gusperimus
:L04AA22 Abetimus
:L04AA24 Abatacept
:L04AA28 Belatacept
:L04AA32 Apremilast
:L04AA40 Cladribine
:L04AA41 Imlifidase
:L04AA48 Belumosudil
:L04AA60 Remibrutinib
:L04AA61 Nerandomilast
:L04AA62 Tolebrutinib
<span class="anchor" id="L04AB"></span>L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
:L04AB01 Etanercept
:L04AB02 Infliximab
:L04AB03 Afelimomab
:L04AB04 Adalimumab
:L04AB05 Certolizumab pegol
:L04AB06 Golimumab
:L04AB07 Opinercept
<span class="anchor" id="L04AC"></span>L04AC Interleukin inhibitors
:L04AC01 Daclizumab
:L04AC02 Basiliximab
:L04AC03 Anakinra
:L04AC04 Rilonacept
:L04AC05 Ustekinumab
:L04AC07 Tocilizumab
:L04AC08 Canakinumab
:L04AC09 Briakinumab
:L04AC10 Secukinumab
:L04AC11 Siltuximab
:L04AC12 Brodalumab
:L04AC13 Ixekizumab
:L04AC14 Sarilumab
:L04AC15 Sirukumab
:L04AC16 Guselkumab
:L04AC17 Tildrakizumab
:L04AC18 Risankizumab
:L04AC19 Satralizumab
:L04AC20 Netakimab
:L04AC21 Bimekizumab
:L04AC22 Spesolimab
:L04AC23 Olokizumab
:L04AC26 Goflikicept
:L04AC27 Cendakimab
<span class="anchor" id="L04AD"></span>L04AD Calcineurin inhibitors
:L04AD01 Ciclosporin
:L04AD02 Tacrolimus
:L04AD03 Voclosporin
<span class="anchor" id="L04AE"></span>L04AE Sphingosine 1-phosphate (S1P) receptor modulators
:L04AE01 Fingolimod
:L04AE02 Ozanimod
:L04AE03 Siponimod
:L04AE04 Ponesimod
:L04AE05 Etrasimod
<span class="anchor" id="L04AF"></span>L04AF Janus-associated kinase (JAK) inhibitors
:L04AF01 Tofacitinib
:L04AF02 Baricitinib
:L04AF03 Upadacitinib
:L04AF04 Filgotinib
:L04AF05 Itacitinib
:L04AF06 Peficitinib
:L04AF07 Deucravacitinib
:L04AF08 Ritlecitinib
:L04AF09 Deuruxolitinib
<span class="anchor" id="L04AG"></span>L04AG Monoclonal antibodies
:L04AG01 Muromonab-CD3
:L04AG02 Efalizumab
:L04AG03 Natalizumab
:L04AG04 Belimumab
:L04AG05 Vedolizumab
:L04AG06 Alemtuzumab
:L04AG07 Begelomab
:L04AG08 Ocrelizumab
:L04AG09 Emapalumab
:L04AG10 Inebilizumab
:L04AG11 Anifrolumab
:L04AG12 Ofatumumab
:L04AG13 Teprotumumab
:L04AG14 Ublituximab
:L04AG15 Divozilimab
:L04AG17 Seniprutug
:L04AG18 Sibeprenlimab
:L04AG19 Axatilimab
<span class="anchor" id="L04AH"></span>L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
:L04AH01 Sirolimus
:L04AH02 Everolimus
<span class="anchor" id="L04AJ"></span>L04AJ Complement inhibitors
:L04AJ01 Eculizumab
:L04AJ02 Ravulizumab
:L04AJ03 Pegcetacoplan
:L04AJ04 Sutimlimab
:L04AJ05 Avacopan
:L04AJ06 Zilucoplan
:L04AJ07 Crovalimab
:L04AJ08 Iptacopan
:L04AJ09 Danicopan
:L04AJ10 Vilobelimab
:L04AJ11 Pozelimab
<span class="anchor" id="L04AK"></span>L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors
:L04AK01 Leflunomide
:L04AK02 Teriflunomide
<span class="anchor" id="L04AL"></span>L04AL Neonatal fragment crystallizable receptor (FcRn) inhibitors
:L04AL01 Efgartigimod alfa
:L04AL02 Rozanolixizumab
:L04AL03 Nipocalimab
<span class="anchor" id="L04AX"></span>L04AX Other immunosuppressants
:L04AX01 Azathioprine
:L04AX02 Thalidomide
:L04AX03 Methotrexate
:L04AX04 Lenalidomide
:L04AX05 Pirfenidone
:L04AX06 Pomalidomide
:L04AX07 Dimethyl fumarate
:L04AX08 Darvadstrocel
:L04AX09 Diroximel fumarate
:L04AX10 Tegomil fumarate
:L04AX11 Monomethyl fumarate